Insider trade

CFO sold ~$390K of GILD shares in the open market

Traded Jul 15, 2026 · Filed Jul 16, 2026

~$390K
Reported value · 3,000 sh @ $129.9256: 169K
Holds after · shares reported: +12.0%
stock since the trade · S&P 500 +1.2%, $131.70 → $147.50 on Oct 1

Why it stands out

The money chief of Gilead Sciences sold $390K of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 15, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 16, 2026

CFO$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$389,777

Shares × reported transaction price

Timing vs results

69 days after results of May 7, 2026, 20 days before results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $131.70 on Jul 15, 2026, 22% above its 52-week low and 15% below its high, little changed over the previous 30 trading days

52-week range $108.22 (Jul 18, 2025) to $155.80 (Feb 11, 2026), 49% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.10 on Jun 1, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Trodelvy on Jun 24, 2026, 21 days before this trade.

New use approved (efficacy supplement). Active ingredient: Sacituzumab Govitecan-Hziy. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-3.7%	-0.6%	-3.1%
30 days	+3.5%	+4.0%	-0.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001310204-26-000022
Filed / recorded: Jul 16, 2026, 10:08 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: GILEAD SCIENCES, INC.
Issuer CIK: 882095
Ticker: GILD
Reporting person: Andrew D Dickinson
Relationship: Officer
Officer title: Chief Financial Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jul 15, 2026
Transaction code: S
Shares / units: 3,000
Price per share: $129.9256
Acquired / disposed: Disposed (D)
Shares owned after: 168,646
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.